TY - JOUR
T1 - Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD)
AU - Khoury, Paneez
AU - Akuthota, Praveen
AU - Ackerman, Steven J.
AU - Arron, Joseph R.
AU - Bochner, Bruce S.
AU - Collins, Margaret H.
AU - Kahn, Jean Emmanuel
AU - Fulkerson, Patricia C.
AU - Gleich, Gerald J.
AU - Gopal-Srivastava, Rashmi
AU - Jacobsen, Elizabeth A.
AU - Leiferman, Kristen M.
AU - Francesca, Levi Schaffer
AU - Mathur, Sameer K.
AU - Minnicozzi, Michael
AU - Prussin, Calman
AU - Rothenberg, Marc E.
AU - Roufosse, Florence
AU - Sable, Kathleen
AU - Simon, Dagmar
AU - Simon, Hans Uwe
AU - Spencer, Lisa A.
AU - Steinfeld, Jonathan
AU - Wardlaw, Andrew J.
AU - Wechsler, Michael E.
AU - Weller, Peter F.
AU - Klion, Amy D.
N1 - Publisher Copyright:
©2018 Society for Leukocyte Biology
PY - 2018/7
Y1 - 2018/7
N2 - Eosinophil-associated diseases (EADs) are rare, heterogeneous disorders characterized by the presence of eosinophils in tissues and/or peripheral blood resulting in immunopathology. The heterogeneity of tissue involvement, lack of sufficient animal models, technical challenges in working with eosinophils, and lack of standardized histopathologic approaches have hampered progress in basic research. Additionally, clinical trials and drug development for rare EADs are limited by the lack of primary and surrogate endpoints, biomarkers, and validated patient-reported outcomes. Researchers with expertise in eosinophil biology and eosinophil-related diseases reviewed the state of current eosinophil research, resources, progress, and unmet needs in the field since the 2012 meeting of the NIH Taskforce on the Research of Eosinophil-Associated Diseases (TREAD). RE-TREAD focused on gaps in basic science, translational, and clinical research on eosinophils and eosinophil-related pathogenesis. Improved recapitulation of human eosinophil biology and pathogenesis in murine models was felt to be of importance. Characterization of eosinophil phenotypes, the role of eosinophil subsets in tissues, identification of biomarkers of eosinophil activation and tissue load, and a better understanding of the role of eosinophils in human disease were prioritized. Finally, an unmet need for tools for use in clinical trials was emphasized. Histopathologic scoring, patient- and clinician-reported outcomes, and appropriate coding were deemed of paramount importance for research collaborations, drug development, and approval by regulatory agencies. Further exploration of the eosinophil genome, epigenome, and proteome was also encouraged. Although progress has been made since 2012, unmet needs in eosinophil research remain a priority.
AB - Eosinophil-associated diseases (EADs) are rare, heterogeneous disorders characterized by the presence of eosinophils in tissues and/or peripheral blood resulting in immunopathology. The heterogeneity of tissue involvement, lack of sufficient animal models, technical challenges in working with eosinophils, and lack of standardized histopathologic approaches have hampered progress in basic research. Additionally, clinical trials and drug development for rare EADs are limited by the lack of primary and surrogate endpoints, biomarkers, and validated patient-reported outcomes. Researchers with expertise in eosinophil biology and eosinophil-related diseases reviewed the state of current eosinophil research, resources, progress, and unmet needs in the field since the 2012 meeting of the NIH Taskforce on the Research of Eosinophil-Associated Diseases (TREAD). RE-TREAD focused on gaps in basic science, translational, and clinical research on eosinophils and eosinophil-related pathogenesis. Improved recapitulation of human eosinophil biology and pathogenesis in murine models was felt to be of importance. Characterization of eosinophil phenotypes, the role of eosinophil subsets in tissues, identification of biomarkers of eosinophil activation and tissue load, and a better understanding of the role of eosinophils in human disease were prioritized. Finally, an unmet need for tools for use in clinical trials was emphasized. Histopathologic scoring, patient- and clinician-reported outcomes, and appropriate coding were deemed of paramount importance for research collaborations, drug development, and approval by regulatory agencies. Further exploration of the eosinophil genome, epigenome, and proteome was also encouraged. Although progress has been made since 2012, unmet needs in eosinophil research remain a priority.
KW - biomarkers
KW - eosinophil-related disorders
KW - eosinophilia
KW - hypereosinophilic syndromes
KW - murine models
KW - translational research
UR - http://www.scopus.com/inward/record.url?scp=85048806358&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048806358&partnerID=8YFLogxK
U2 - 10.1002/JLB.5MR0118-028R
DO - 10.1002/JLB.5MR0118-028R
M3 - Review article
C2 - 29672914
AN - SCOPUS:85048806358
SN - 0741-5400
VL - 104
SP - 69
EP - 83
JO - Journal of Leukocyte Biology
JF - Journal of Leukocyte Biology
IS - 1
ER -